Teva closing in on $40B buy of Allergan generics unit
Teva’s acquisition will make it the world’s largest maker of generic medicines, giving it greater negotiating power with governments and private-health insurers.
Eli Lilly and Co.
Articles
UPDATE: Lilly meets quarterly expectations but trims forecast
Strong sales of drugs for diabetes, cancer and animals helped the Indianapolis drugmaker overcome falling sales of older drugs for depression and osteoporosis, pushing up fourth-quarter sales and profit.
Lilly’s 2016 sales, profit guidance falls short of predictions
Indianapolis-based Eli Lilly and Co., which has promised to return to growth after a half-decade of falling revenue, indicated that 2016 earnings might be below analysts’ estimates.
Lilly could pay $800M-plus in pact with drug-tech firm
The companies will work on coupling therapies from Lilly with technology from Halozyme Therapeutics that helps the body disperse and spread medicine.
FDA OKs once-a-day insulin that could be blockbuster for Lilly
The FDA said Wednesday it approved Basaglar based on data showing it is safe and effective and works similarly to Lantus, the world’s top-selling insulin.
Lilly’s latest dividend increase carries on long tradition
Until impending patent expirations spurred the company to forgo a dividend increase in 2010, the company had announced dividend increases for 42 consecutive years.
Lilly separating manufacturing of animal health drugs
Eli Lilly and Co. is in the process of separating the manufacturing of its animal health drugs from the facilities used to make its traditional pharmaceuticals, a move that potentially could make it easier to spin off the division one day.
Eli Lilly ends development of promising insulin drug
Eli Lilly said Friday that it decided to stop developing the insulin peglispro after learning that it would take more time and cost more than expected to understand a significant side effect.
Firms start early trying to entice science-oriented students
Dozens of companies across central Indiana are using programs aimed at middle- and high-school students to develop a pool of talented kids who are interested in science, technology, engineering and math to fill the growing number of jobs for which such skills are necessary.
U.S. doctors group calls for drug advertising ban
In a vote Tuesday, the American Medical Association called for an end to television commercials and magazine spreads that are used to pitch prescription drugs directly to consumers.
Despite wealth of attention, new female libido pill isn’t selling
The number of prescriptions for Addyi, the women’s libido-boosting pill, in its first few weeks? 227.
Lilly, other drugmakers face federal pricing probe
Indianapolis-based Eli Lilly and Co. and other U.S. drugmakers are being investigated by federal prosecutors over their drug-pricing practices related to Medicare and Medicaid, according to newspaper reports.
UPDATE: Eli Lilly to build $70M R&D building in Indianapolis
The 130,000-square-foot building will be designed to encourage collaboration among scientists across different disciplines, which the company said is crucial to fostering innovation.
Elanco president makes case for juiced-up cows in organic age
Jeff Simmons is on a counteroffensive as, increasingly, the drugs that Elanco makes—including antibiotics and productivity enhancers—have come under attack by food activists.
Lilly predicts higher profits after better-than-expected quarter
Eli Lilly and Co. beat Wall Street’s expectations with its third-quarter profit, prompting the drugmaker to raise its full-year forecast by as much as 20 cents per share.
Pharmaceutical firms losing business to darknet drug deals
For the $300 billion pharmaceutical industry, the rapid growth of illegal underground marketplaces is a serious threat to profits and reputations.
Lilly competitor fails to win FDA backing for diabetes treatment
AstraZeneca Plc didn’t receive U.S. approval for a new diabetes treatment that combines two of its existing drugs. The combination would have competed with Glyxambi from Lilly.
UPDATE: Lilly halts work on potential blockbuster cholesterol drug
Eli Lilly shares plunged nearly 10 percent Monday morning after it said it would stop development of evacetrapib, an experimental cholesterol drug with blockbuster potential.
Lilly expands China drug partnership in growing cancer market
Suzhou, China-based Innovent could receive payments totaling more than $1 billion if the cancer products it develops with Lilly reach certain milestones.
Lilly to add 50 employees at R&D center in New York
The drugmaker is trying to beef up its work on using the immune system to fight cancer. Indianapolis will remain Lilly’s main hub for research and development.